CIHR Research Excellence Diversity and Independence (REDI) 2025 Early Career Transition Award: Information Sessions
Knowledge Exchange Sessions – Acceptance of adaptive aids and equipment
ICNMDigital 2025
NMJ episode 2: Update on antibodies in Neuromuscular Junction Disorders
Myogenesis Discussion Group | November 2025
NMJ episode 3: Innovative therapies in Myasthenia Gravis
Date: Wednesday 26 November 2025
Time: 16:00 CEST / 10:00 EDT
Speaker: Prof. Dr. med. Andreas Meisel | Charité – Universitätsmedizin Berlin (CCM), Germany.
Andreas Meisel is a professor of neurology at the Center for Stroke Research Berlin (CSB) and NeuroCure Clinical Research Center (NCRC), and an attending physician and neurointensivist in the Department of Neurology with Experimental Neurology. He is chairman of the Berlin Stroke Alliance. His group is active in experimental and clinical stroke research unravelling mechanisms of stroke induced immune changes and its functional relevance for post-stroke complications as well as brain repair. Meisel’s group is developing novel diagnostic biomarkers and treatments for post-stroke complications. Moreover, he aims at establishing comprehensive care approaches for stroke survivors in the chronic phase of the disorder.
Topic: NMJ episode 3: Innovative therapies in Myasthenia Gravis
Disclaimer:
This is a EURO-NMD webinar in collaboration with ERN-RND (rare neurological disorders) and European Academy of Neurology. By registering and attending the webinar you consent to the recording of the webinar and its later diffusion through the EURO-NMD websites using an YouTube Channel